Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evaxion A (EVAX) Receivables (2019 - 2023)

Evaxion A posted quarterly Receivables of $2.1 million for Q4 2023, down 26.45% year-on-year from $2.8 million in Q4 2022, and down 26.45% on a QoQ basis from $2.8 million in Q4 2022.

Evaxion A (EVAX) has 5 years of Receivables data on file, last reported at $2.1 million in Q4 2023.

  • For the quarter ending Q4 2023, Receivables fell 26.45% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2023 stood at $2.1 million (down 26.45% YoY), and the FY2023 full-year result was $2.1 million, down 26.45% from the prior year.
  • Receivables for Q4 2023 stood at $2.1 million, down from $2.8 million in the prior quarter.
  • Across five years, Receivables topped out at $2.8 million in Q4 2022 and bottomed at $607000.0 in Q4 2019.
  • The 5-year median for Receivables is $1.6 million (2020), against an average of $1.7 million.
  • The widest annual swing landed in 2020, when Receivables jumped 157.0%; it then dropped 26.45% in 2023.
  • A 5-year view of Receivables shows it stood at $607000.0 in 2019, then surged by 157.0% to $1.6 million in 2020, then fell by 19.81% to $1.3 million in 2021, then soared by 123.9% to $2.8 million in 2022, then fell by 26.45% to $2.1 million in 2023.
  • The last three Receivables figures came in at $2.1 million (Q4 2023), $2.8 million (Q4 2022), and $1.3 million (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 13.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 4.15 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.00 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 5.73 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 883.96 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 2.06 Mn
Dec 31, 2022 2.80 Mn
Dec 31, 2021 1.25 Mn
Dec 31, 2020 1.56 Mn
Dec 31, 2019 607,000.00